COVID-19

Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate

Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary…

2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE…

2 years ago

BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Westport, CT, June 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology…

2 years ago

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference

FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

2 years ago

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…

2 years ago

ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

All resolutions were approved.35% of the issued shares represented.MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

2 years ago

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

2 years ago

Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into…

2 years ago

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared…

2 years ago